CARDIFF, UK / ACCESS Newswire / February 19, 2026 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment ...
March 9, 2026Biodexa Announces Support for Life’s a Polyp FoundationFirst U.S. Patient Advocacy Group for FAP Patients ...
Researchers at the Cancer Research Institute and the Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, have ...
GISTs originate from interstitial cells of Cajal and are staged by size, location, mitotic rate, and genetic mutations, influencing treatment strategies. Diagnosis involves imaging, endoscopy, biopsy, ...
GIST originates in stromal tissue, differentiating it from epithelial-based GI cancers, and is classified as a sarcoma. Symptoms include fullness, fatigue, and GI bleeding, necessitating awareness and ...
New Data Demonstrates Significant Reduction in Tumor Growth and KIT Expression in Preclinical GIST Models Induction of Tumor Cell Death – HT-KIT triggered significant tumor cell death as early as 24 ...
The optimal duration of adjuvant imatinib has yet to be determined, and clinical trials are ongoing to address this. KIT-directed tyrosine kinase inhibitors (TKIs) are the key treatment for advanced ...
Less than 5% of GI stromal tumors (GISTs) are driven by the loss of the succinate dehydrogenase (SDH) complex, resulting in a pervasive DNA hypermethylation pattern that leads to unique clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results